NeuroMetrix Reports Commercial Milestone 100th NC-stat® DPNCheck™ Order

NeuroMetrix Reports Commercial Milestone 100th NC-stat® DPNCheck™ OrderWALTHAM, Mass.--(BUSINESS WIRE)--Dec. 28, 2011-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, today announced the achievement of a commercial milestone when it received its 100^th NC-stat^® DPNCheck™ order. NC-stat DPNCheck is a fast, accurate and quantitative point-of-care test for the evaluation of systemic neuropathies such as diabetic peripheral neuropathy (DPN). The NC-stat DPNCheck device measures sural nerve conduction velocity and amplitude which are recognized early and quantitative biomarkers for DPN. DPN affects more than half of people with diabetes and may lead to foot ulcers and limb amputation, as well as pain and an overall reduction in quality of life. NeuroMetrix believes that the NC-stat DPNCheck test may address the unmet medical need for better, cost-effective approaches to detecting and monitoring DPN.

“We are pleased with initial market reaction to NC-stat DPNCheck” said Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer. “Approximately 200 physicians, mostly endocrinologists and podiatrists, in 100 medical practices are now using the device to improve their management of DPN. This achievement comes three months after commercial launch. Ultimately, we hope to achieve broad adoption in both the US and international markets where we believe NC-stat DPNCheck will enhance the ability of physicians to detect and stage DPN leading to earlier and more targeted clinical interventions benefiting patient care and reducing health care costs.”

About NeuroMetrix

NeuroMetrix is a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes. The Company currently markets products for the detection, diagnosis, and monitoring of diabetic neuropathies such as diabetic peripheral neuropathy and median neuropathy (carpal tunnel syndrome). For more information, please visit www.neurometrix.com.

Source: NeuroMetrix

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
Chief Financial Officer
neurometrix.ir@neurometrix.com